scholarly journals Effects of Dialysate Flow Configurations in Continuous Renal Replacement Therapy on Solute Removal: Computational Modeling

2013 ◽  
Vol 35 (1-3) ◽  
pp. 106-111 ◽  
Author(s):  
Jeong Chul Kim ◽  
Dinna Cruz ◽  
Francesco Garzotto ◽  
Manish Kaushik ◽  
Catarina Teixeria ◽  
...  
Antibiotics ◽  
2021 ◽  
Vol 10 (10) ◽  
pp. 1184
Author(s):  
Soo Min Jang ◽  
Lenar Yessayan ◽  
Michael Dean ◽  
Gabrielle Costello ◽  
Ravi Katwaru ◽  
...  

(1) Purpose of this study: determination of adsorption and transmembrane clearances (CLTM) of imipenem and relebactam in ex vivo continuous hemofiltration (CH) and continuous hemodialysis (CHD) models. These clearances were incorporated into a Monte Carlo Simulation (MCS), to develop drug dosing recommendations for critically ill patients requiring continuous renal replacement therapy (CRRT); (2) Methods: A validated ex vivo bovine blood CH and CHD model using two hemodiafilters. Imipenem/relebactam and urea CLTM at different ultrafiltrate/dialysate flow rates were evaluated in both CH and CHD. MCS was performed to determine dose recommendations for patients receiving CRRT; (3) Results: Neither imipenem nor relebactam adsorbed to the CRRT apparatus. The CLTM of imipenem, relebactam, and urea approximated the effluent rates (ultrafiltrate/dialysate flow rates). The types of hemodiafilter and effluent rates did not influence CLTM except in a dialysis flow rate of 1 L/h and 6 L/h in the CHD with relebactam (p < 0.05). Imipenem and relebactam 200 mg/100 mg every 6 h were sufficient to meet the standard time above the MIC pharmacodynamic targets in the modeled CRRT regimen of 25 kg/mL/h. (4) Conclusions: Imipenem and relebactam are not removed by adsorption to the CRRT apparatus, but readily cross the hemodiafilter membrane in CH and CHD. Dosage adjustment of imipenem/relebactam is likely required for critically ill patients receiving CRRT.


2019 ◽  
Vol 42 (7) ◽  
pp. 354-361
Author(s):  
Wenyan Yu ◽  
Feng Zhuang ◽  
Shuai Ma ◽  
Mingli Zhu ◽  
Feng Ding

Background:Some studies suggest the effluent as a surrogate solute removal indicator in continuous hemodialysis or hemofiltration, but the delivered clearance is frequently smaller than prescribed. This study aims at testing whether the effluent, represented by mL/kg/h, could measure solute clearance and whether increasing effluent increases clearance proportionately in continuous hemodialysis or hemofiltration.Methods:Patients treated with continuous renal replacement therapy for various diagnoses were included. The range of dialysate flow rate or substitution fluid flow rate was 1–5 L/h; solutes in the effluent and in the plasma entering the filter were measured, and the ratio of solutes in the effluent and in the plasma entering the filter and the clearance of blood urea nitrogen, creatinine, phosphate, and β2-microglobulin were calculated.Results:The ratio of solutes in the effluent and in the plasma entering the filter showed a decreasing trend with increased dialysate flow rate or substitution fluid flow rate ( p  < 0.05), but solute clearance showed an increasing trend. The increase in solute clearance was less than expected from the increased effluent ( p < 0.01), and actual delivered clearance was always below the corresponding prescribed clearance ( p < 0.001).Conclusion:With increasing prescribed clearance of continuous renal replacement therapy, effluent rate overestimated the delivered clearance.


Sign in / Sign up

Export Citation Format

Share Document